Traditional chemotherapy may fail to achieve complete remission of cancers due to resistance of the underlying cancer stem cells (CSCs) to the therapeutic agents. It is now well accepted that to achieve greater efficacy there is a need to specifically target CSCs within a tumor cell population. Furthermore, understanding the self-renewal potential of these CSCs, as well as their susceptibility to drug treatment and the overall malignant potential of the cancer, are essential steps to more successful cancer therapy.
Researchers at UC San Diego have developed a method for determining the self-renewal potential of CSCs. This technology involves CSC-specific analysis and quantitation of key players (splice variants of proteins and transcripts) in metabolic pathways that are critical for cell survival and self-renewal. The analysis of the cross-talk within cell survival and self-renewal pathways enables the:
Validation experiments confirm cell type and context specific deregulation of apoptosis via deregulated expression in the CSC population. In vivo studies on CSC engraftment validate the therapeutic potential of targeting survival pathways and in vitro studies suggest mechanism of action.
Pending U.S. patent application 20110059448.
Country | Type | Number | Dated | Case |
United States Of America | Issued Patent | 10,001,485 | 06/19/2018 | 2012-155 |
United States Of America | Issued Patent | 9,194,862 | 11/24/2015 | 2009-187 |
self-renewal, cancer stem cell, leukemia, apoptosis, survival, Bcl-2, Bcl-XL, Mcl-1, Wnt, GSK3, GSK-3, glycogen synthase kinase, hedgehog, Shh, transcript, splice variant, isoform, expression, biomarker